•
Jun 30, 2021
Corcept Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided a corporate update.
Key Takeaways
Corcept Therapeutics reported a revenue of $91.6 million for Q2 2021, compared to $88.6 million in Q2 2020. GAAP diluted net income was $0.21 per share, and non-GAAP diluted net income was $0.30 per share. The company reiterated its 2021 revenue guidance of $355 – $385 million.
Revenue of $91.6 million, compared to $88.6 million in second quarter 2020
GAAP diluted net income of $0.21 per share, compared to $0.23 per share in second quarter 2020
Non-GAAP diluted net income of $0.30 per share, compared to $0.32 per share in second quarter 2020
Cash and investments of $471.6 million, compared to $454.8 million at March 31, 2021
Corcept Therapeutics
Corcept Therapeutics
Forward Guidance
The company reiterated its 2021 revenue guidance of $355 – $385 million.